Search

Author/Creator Fischer, Hans Holger

1. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Issue 5 (May 2022)

Authors:
Nitz, Ulrike; Gluz, Oleg; Graeser, Monika; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Braun, Michael; Augustin, Doris; Potenberg, Jochem; Krauss, Katja; Schumacher, Claudia; Forstbauer, Helmut; Reimer, Toralf; Stefek, Andrea; Fischer, Hans Holger; Pelz, Enrico; zu Eulenburg, Chris...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 5(2022)
Page Start:
625
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials. Issue 10 (11th February 2021)

Authors:
Graeser, Monika; Schrading, Simone; Gluz, Oleg; Strobel, Kevin; Würstlein, Rachel; Kümmel, Sherko; Schumacher, Claudia; Grischke, Eva‐Maria; Forstbauer, Helmut; Braun, Michael; Christgen, Matthias; Adams, Jascha; Nitzsche, Henrik; Just, Marianne; Fischer, Hans Holger; Aktas, Bahriye; Potenberg, J...
Journal:
International journal of cancer
Issue:
Volume 148:Issue 10(2021)
Page Start:
2614
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search